Transferred Immunity
转移免疫
基本信息
- 批准号:10203490
- 负责人:
- 金额:$ 54.41万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-07-12 至 2026-04-30
- 项目状态:未结题
- 来源:
- 关键词:AffectAffinityAnimal ModelAntibodiesAntibody RepertoireAntibody TherapyAntigensAreaAutoimmunityB cell repertoireBindingBiochemicalBiodistributionBiologicalBiologyBiophysicsBirthBloodBlood specimenBreast FeedingChildCommunicable DiseasesCoupledDevelopmentEngineeringEvaluationFc ReceptorFetal healthFetusFutureGenomicsHalf-LifeHealthHumanHuman MilkHumoral ImmunitiesImmunityImmunoglobulin AImmunoglobulin GImmunologicsIn VitroInfantInheritedIntrinsic factorKnowledgeLeadLinkMass Spectrum AnalysisMaternal antibodyMaternal-fetal medicineMeasurementMediatingMedicineMilkModelingMolecularMonoclonal Antibody TherapyMorbidity - disease rateMothersNatural ImmunityNeonatalOutcomePathologicPhenotypePlacentaPlayPregnancyPregnant WomenProteomicsRecyclingReportingResolutionRoleSamplingSerumShapesSpecificityTechniquesTherapeutic antibodiesTimeUmbilical Cord BloodVaccinatedVaccinationVaccine AntigenVaccine TherapyVaccinesVariantWorkadaptive immune responseantibody engineeringantibody transfercritical perioddesignfetalhigh riskimmunogenicityimprovedin uteroin vivo Modelin vivo evaluationinfant morbidity/mortalityinnovationinsightmaternal vaccinationmolecular phenotypemortalitymultiple omicsnatural antibodiesneglectneonatal Fc receptorneonatal healthneonatal morbidityneonatenext generation sequencingnon-Nativenovelnovel therapeuticspassive antibodiespathogenpostnatalprotective effectreceptorreceptor expressionresponsesuccesstargeted treatmenttissue culturetoolvaccine developmentvaccine responsevaccine-induced antibodies
项目摘要
PROJECT 2 - ABSTRACT
This project proposes to better understand the mechanisms governing, and advance our ability to
rationally control maternal-fetal antibody transport. By comparing the profiles of antibodies from milk and from
blood samples during pregnancy and umbilical cord blood samples after birth using high-throughput proteomic
tools such as NextGen sequencing of the maternal B cell repertoire and high-resolution proteomic analysis by
mass spectrometry, IgG glycoprofiling, Fc receptor affinity characterization, and Ig isotyping and subclassing,
we will define phenotypic biases in global and antigen/ vaccine-specific Ab repertoires transferred to the fetus
in vaccinated and unvaccinated pregnancies, and quantify the degree of similarity of the antibody repertoire
between mother and child. In vivo evaluation of the relationship between antibody half-life and placental
transport in animal models using natural and engineered IgG variants will define the extent of linkage between
different biological roles of FcRn, and evaluation of existing and engineering of novel IgG Fc variants for
enhanced placental transport in the ex vivo human placenta model will be employed to identify Abs with altered
transport phenotypes. Our overarching hypotheses are that among natural and engineered antibody molecules
there exist intrinsic biases for certain antibody molecules to transport across placenta more and less efficiently.
Discovery and knowledge of these biases will contribute to development of vaccine and therapeutic antibody
strategies with increased or decreased transport efficiency that are designed to improve health outcomes for
mothers and the fetus/neonate during this critical period of immunological development.
项目 2 - 摘要
该项目旨在更好地理解治理机制,并提高我们的能力
合理控制母胎抗体转运。通过比较牛奶和来自
使用高通量蛋白质组学分析怀孕期间的血液样本和出生后的脐带血样本
母体 B 细胞库的 NextGen 测序和高分辨率蛋白质组分析等工具
质谱分析、IgG 糖谱分析、Fc 受体亲和力表征以及 Ig 同型分型和子分类,
我们将定义转移到胎儿的整体和抗原/疫苗特异性抗体库的表型偏差
在接种疫苗和未接种疫苗的妊娠中,量化抗体库的相似程度
母亲和孩子之间。抗体半衰期与胎盘关系的体内评估
使用天然和工程化 IgG 变体的动物模型中的运输将定义之间的联系程度
FcRn 的不同生物学作用,以及新型 IgG Fc 变体的现有和工程评估
离体人胎盘模型中增强的胎盘转运将用于鉴定具有改变的抗体
运输表型。我们的首要假设是,在天然和工程抗体分子中
某些抗体分子通过胎盘转运的效率存在固有偏差。
这些偏见的发现和了解将有助于疫苗和治疗性抗体的开发
提高或降低运输效率的策略旨在改善健康结果
母亲和胎儿/新生儿在免疫发育的关键时期。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Margaret E Ackerman其他文献
Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial.
向未感染 HIV 的成人静脉注射抗 HIV 单克隆抗体 PGT121、PGDM1400、10-1074 和 VRC07-523LS 的双重组合和三重组合的安全性、耐受性、药代动力学和免疫活性:一项 1 期随机试验。
- DOI:
10.1016/s2352-3018(23)00140-6 - 发表时间:
2023-10-01 - 期刊:
- 影响因子:0
- 作者:
Magdalena E. Sobieszczyk;Sharon Mannheimer;Carmen A Paez;Chenchen Yu;Theresa Gamble;Deborah A. Theodore;Wairimu Chege;Margaret Yacovone;Brett Hanscom;Jack R. Heptinstall;K. Seaton;Lily Zhang;Maurine D. Miner;Amanda Eaton;Joshua A. Weiner;Kenneth H. Mayer;Spyros A. Kalams;Kathryn Stephenson;B. Julg;Marina Caskey;M. Nussenzweig;Lucio Gama;D. Barouch;Margaret E Ackerman;G. Tomaras;Yunda Huang;David C. Montefiori - 通讯作者:
David C. Montefiori
Mapping the journey to an HIV vaccine.
绘制艾滋病毒疫苗的研发历程。
- DOI:
10.1056/nejmcibr1304437 - 发表时间:
2013-07-24 - 期刊:
- 影响因子:0
- 作者:
Margaret E Ackerman;Galit Alter - 通讯作者:
Galit Alter
Selection of positive controls and their impact on anti-drug antibody assay performance.
阳性对照的选择及其对抗药物抗体测定性能的影响。
- DOI:
- 发表时间:
2024 - 期刊:
- 影响因子:0
- 作者:
Joshua A. Weiner;H. Natarajan;Calum J. McIntosh;E. Yang;Misook Choe;Cassidy L. Papia;Katherine S Axelrod;Gabriela Kovacikova;A. Pegu;Margaret E Ackerman - 通讯作者:
Margaret E Ackerman
Margaret E Ackerman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Margaret E Ackerman', 18)}}的其他基金
IgG and FcR Characterization in Small Animal Models of RespiratoryDisease
呼吸道疾病小动物模型中的 IgG 和 FcR 表征
- 批准号:
10678229 - 财政年份:2023
- 资助金额:
$ 54.41万 - 项目类别:
Understanding and optimizing antibody-based interventions against neonatal HSV infection
了解和优化针对新生儿 HSV 感染的抗体干预措施
- 批准号:
10752835 - 财政年份:2023
- 资助金额:
$ 54.41万 - 项目类别:
New analytic approaches and endpoints in human HIV vaccine correlate studies
人类艾滋病毒疫苗相关研究的新分析方法和终点
- 批准号:
10613609 - 财政年份:2022
- 资助金额:
$ 54.41万 - 项目类别:
Applying High-Performance Protein Engineering Tools to HIV Immunogen Design
将高性能蛋白质工程工具应用于 HIV 免疫原设计
- 批准号:
8513258 - 财政年份:2012
- 资助金额:
$ 54.41万 - 项目类别:
Applying High-Performance Protein Engineering Tools to HIV Immunogen Design
将高性能蛋白质工程工具应用于 HIV 免疫原设计
- 批准号:
8409958 - 财政年份:2012
- 资助金额:
$ 54.41万 - 项目类别:
Applying High-Performance Protein Engineering Tools to HIV Immunogen Design
将高性能蛋白质工程工具应用于 HIV 免疫原设计
- 批准号:
8686742 - 财政年份:2012
- 资助金额:
$ 54.41万 - 项目类别:
相似国自然基金
抗原非特异性B细胞进入生发中心并实现亲和力成熟的潜力与调控机制
- 批准号:32370941
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
基于胞内蛋白亲和力标记策略进行新型抗类风湿性关节炎的选择性OGG1小分子抑制剂的发现
- 批准号:82304698
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
面向免疫疗法标志物识别的基于多特征融合的肽与MHC亲和力预测研究
- 批准号:62302277
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于计算生物学技术小分子农兽药残留物驼源单域抗体虚拟筛选与亲和力成熟 -以内蒙古阿拉善双峰驼为例
- 批准号:32360190
- 批准年份:2023
- 资助金额:34 万元
- 项目类别:地区科学基金项目
DNA四面体限域辅助的高亲和力铅笔芯微电极用于早期癌症精准诊断研究
- 批准号:22304062
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Selective Inhibitors of T Cell Activation Target Exportin-1 at Cys528 to Suppress Pathological T Cell Activation
T 细胞激活的选择性抑制剂 Cys528 靶点 Exportin-1 抑制病理性 T 细胞激活
- 批准号:
10659905 - 财政年份:2023
- 资助金额:
$ 54.41万 - 项目类别:
Structure of GDAP1 bound to a product of lipid peroxidation
与脂质过氧化产物结合的 GDAP1 的结构
- 批准号:
10645396 - 财政年份:2023
- 资助金额:
$ 54.41万 - 项目类别:
Partial and Controlled Depletion of SR Calcium by RyR Agonists Prevents Calcium-dependent Arrhythmias
RyR 激动剂部分且受控地消耗 SR 钙可预防钙依赖性心律失常
- 批准号:
10577630 - 财政年份:2023
- 资助金额:
$ 54.41万 - 项目类别:
Development of caspase-6 inhibitors for treatment of NASH
开发治疗 NASH 的 caspase-6 抑制剂
- 批准号:
10608905 - 财政年份:2023
- 资助金额:
$ 54.41万 - 项目类别:
Small Molecule Therapeutics for Sickle Cell Anemia
镰状细胞性贫血的小分子疗法
- 批准号:
10601679 - 财政年份:2023
- 资助金额:
$ 54.41万 - 项目类别: